Edgestream Partners L.P. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Edgestream Partners L.P. reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 31.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,217 shares of the biopharmaceutical company’s stock after selling 2,422 shares during the quarter. Edgestream Partners L.P.’s holdings in Regeneron Pharmaceuticals were worth $5,483,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of REGN. Gilbert & Cook Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 8.3% in the fourth quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock worth $1,675,000 after buying an additional 146 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its position in shares of Regeneron Pharmaceuticals by 45.2% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,188 shares of the biopharmaceutical company’s stock valued at $1,043,000 after acquiring an additional 370 shares during the period. Avantax Advisory Services Inc. raised its stake in Regeneron Pharmaceuticals by 23.0% in the 4th quarter. Avantax Advisory Services Inc. now owns 1,001 shares of the biopharmaceutical company’s stock worth $879,000 after acquiring an additional 187 shares during the last quarter. Financial Advocates Investment Management raised its stake in Regeneron Pharmaceuticals by 25.6% in the 4th quarter. Financial Advocates Investment Management now owns 393 shares of the biopharmaceutical company’s stock worth $345,000 after acquiring an additional 80 shares during the last quarter. Finally, TrinityPoint Wealth LLC grew its stake in Regeneron Pharmaceuticals by 4.8% during the 4th quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 12 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 0.0 %

Shares of NASDAQ:REGN opened at $1,153.08 on Tuesday. The firm has a market capitalization of $127.05 billion, a price-to-earnings ratio of 34.06, a price-to-earnings-growth ratio of 3.97 and a beta of 0.12. The business’s 50 day moving average price is $1,126.24 and its 200-day moving average price is $1,027.77. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter last year, the business earned $8.79 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the sale, the executive vice president now directly owns 12,931 shares in the company, valued at approximately $13,540,179.41. The disclosure for this sale can be found here. In the last three months, insiders sold 10,026 shares of company stock worth $11,498,705. Corporate insiders own 7.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on REGN shares. Piper Sandler raised their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research note on Friday, August 23rd. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Truist Financial reissued a “buy” rating and set a $1,200.00 target price (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. Finally, Wells Fargo & Company upped their price target on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,109.70.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.